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Disease states such as cancer and other inflammatory conditions often 
show elevated IL-6 levels that correlate with muscle wasting and mortality. 
Previously we reported that STAT3, a transcription factor downstream of IL-6 
binding to its receptor, plays a causative role in cancer cachexia, and that STAT3 
inhibition prevents muscle wasting. Others have also shown that STAT3 
blockade rescues cachexia in a murine model of kidney failure. Altogether these 
results established STAT3 as a regulator of muscle mass. One of STAT3 
downstream target genes is the Suppressor of cytokine signaling-3 (SOCS-3). 
Interestingly, SOCS3 has been reported to inhibit the IL-6/STAT3 signaling by 
means of a feedback mechanism. In particular, SOCS3 can prevent further 
STAT3 activation by inhibiting the activation of JAK kinases, competing for 
receptor binding motifs and targeting the receptor for proteasomal degradation. 
We thus sought to determine the role of SOCS3 in muscle growth regulation and 
whether SOCS3 can improve muscle wasting in conditions of high IL-6.  
Adenoviral-mediated SOCS3 overexpression in C2C12 myotubes caused 
hypertrophy and rescued IL-6-induced myofiber shrinkage. Similarly, SOCS3 
gene transfer in the tibialis muscle of tumor hosts and burn-injured mice 
prevented muscle atrophy due to elevated IL-6. We then generated MLC-SOCS3 
transgenic mice overexpressing SOCS3 from a muscle-specific promoter. 
Interestingly, these animals exhibit a complex sexually dimorphic phenotype. 
Indeed, female mice showed higher SOCS3 protein levels in skeletal muscle 
compared to the males, consistently with decreased pSTAT3 expression. Despite 
reduced or unchanged body weights, the MLC-SOCS3 transgenics generally 
showed larger skeletal muscles compared to their wild-type littermates. 1-week-
old and adult MLC-SOCS3 mice were also characterized by significantly larger 
muscle cross-sectional area. However, only adult male mice showed reduced 
number of muscle fibers and increased number of central nuclei, thus suggesting 
that SOCS3 could affect myogenesis and differentiation. On this line and 
consistent with previous reports, primary myoblasts isolated from MLC-SOCS3 
mice were shown to proliferate at a lower rate and formed hypertrophic fibers 
upon differentiation. Furthermore, MLC-SOCS3 myotubes as well as C2C12 
expressing SOCS3 were refractory to both catabolic (IL-6) and anabolic (IGF-1 
and GH) stimuli.  
These data suggest that SOCS3 could act as a bi-functional regulator of 
muscle growth, possibly by affecting differentiation and limiting both IL-6/STAT3-
induced wasting as well as IGF-1/GH-associated signaling. Further investigation 
is needed to define whether SOCS3 may play a role in the activation of muscle 
satellite cells and to support the use of SOCS3 as a therapeutic approach in 
cachexia and sarcopenia.  
